---
title: "Entera Bio surges 89% on $275M private placement for EB613 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293959369.md"
description: "Entera Bio jumps 89% after announcing a $275M oversubscribed private placement led by BVF Partners."
datetime: "2026-07-27T17:00:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293959369.md)
  - [en](https://longbridge.com/en/news/293959369.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293959369.md)
generator: "portal-rs"
---

# Entera Bio surges 89% on $275M private placement for EB613 trial

Entera Bio(ENTX.US) 盘中涨**89.46%**，现报**3.884 美元**。

公司此前宣布完成**2.75 亿美元**超额认购私募配售，由 BVF Partners 领投，资金将用于资助 EB613 的三期临床研究。

### Related Stocks

- [ENTX.US](https://longbridge.com/en/quote/ENTX.US.md)

## Related News & Research

- [Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%](https://longbridge.com/en/news/295783160.md)
- [Entera Bio (NASDAQ:ENTX) Announces Earnings Results](https://longbridge.com/en/news/295289580.md)
- [Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk](https://longbridge.com/en/news/294234662.md)
- [Entera Bio Q2 FY26 net loss widens to $7.3 million; R&D expenses more than double to $3.2 million](https://longbridge.com/en/news/295272747.md)
- [Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients](https://longbridge.com/en/news/294825410.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**